A Phase 3 interventional study of HLX10 and carboplatin and etoposide in Extensive Stage Small Cell Lung Cancer, sponsored by Shanghai Henlius Biotech. Completed at 5 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-09.
Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of HLX10+ Chemotherapy vs placebo+Chemotherapy in Previously Untreated Patients with Extensive Stage Small Cell Lung Cancer.
Eligible subjects in this study will be randomized to Arm A or Arm B at 2:1 ratio as follows:
Arm A (HLX10 arm): HLX10 + chemotherapy (Carboplatin-Etoposide) ; Arm B (placebo arm): Placebo + chemotherapy (Carboplatin-Etoposide); The three stratification factors for randomization include: PD-L1 expression level (negative, positive, not available), Brain metastasis (yes versus no), Age (≥ 65 years versus \< 65 years)
After screening, subjects meeting the inclusion criteria and none of the exclusion criteria will be enrolled. Included subjects will be treated with HLX10 or placebo in combination with chemotherapy once every 3 weeks, until disease progression, death, intolerable toxicity, withdrawal of informed consent, or occurrence of other reasons specified in the protocol (whichever occurs first).
1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.
This study's enrollment of 585 is above the median of 56 across 1,077 interventional studies indexed under Small Cell Lung Carcinoma.
Browse Small Cell Lung Carcinoma studies →Shanghai Henlius Biotech is the lead sponsor of 132 studies on the registry; 56 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HLX 10+chemotherapy (Carboplatin-Etoposide)
Drug: HLX10 · Drug: carboplatin and etoposide
Placebo+chemotherapy (Carboplatin-Etoposide)
Drug: carboplatin and etoposide · Drug: placebo
HLX10 is an innovative monoclonal antibody targeting PD-1,developed by Shanghai Henlius Biotech, Inc.
Drug pages: Carboplatin · Etoposide
chemotherapeutics
placebo
OS
Overall survival (OS)
Time frame: The period from randomization through death regardless of causality (up to approximately 56 months)
Progression Free Survival (PFS) Assessed by IRRC According to RECIST 1.1
PFS is defined as a period from randomization initiation to the first documentation of PD or death regardless of causality (whichever occurs first).
Time frame: From randomization initiation to the first documentation of PD or death regardless of causality, whichever occurs first (up to approximately 56 months).
Objective Response Rate
The ORR is defined as the proportion of subjects with a best overall response of CR or PR, according to RECIST 1.1. The best overall response will be defined as the best response across all time points in the order of CR, PR, SD, PD, and not NE.
Time frame: From baseline until PR or CR, whichever occurs first (up to approximately 56 months)
Duration of Response
DOR is defined as a period from the first documentation of response (CR or PR) through the first documentation of PD or death (whichever occurs first).
Time frame: From the first documentation of response (CR or PR) through the first documentation of PD or death, whichever occurs first (up to approximately 56 months).
| Milestone | Group A | Group B |
|---|---|---|
| Started | 389 | 196 |
| Completed | 77 | 12 |
| Not completed | 312 | 184 |
| Withdrew: Death | 281 | 166 |
| Withdrew: Lost to follow-up | 12 | 8 |
| Withdrew: Withdrawal by subject | 19 | 10 |
Overall survival (OS)
| month | A Groups | B Groups |
|---|---|---|
| OS | 15.77 (13.897 to 17.413) | 11.10 (9.955 to 12.353) |
PFS is defined as a period from randomization initiation to the first documentation of PD or death regardless of causality (whichever occurs first).
| month | A Groups | B Groups |
|---|---|---|
| Progression Free Survival (PFS) Assessed by IRRC According to RECIST 1.1 | 5.82 (5.552 to 6.932) | 4.34 (4.205 to 4.435) |
The ORR is defined as the proportion of subjects with a best overall response of CR or PR, according to RECIST 1.1. The best overall response will be defined as the best response across all time points in the order of CR, PR, SD, PD, and not NE.
| Participants | A Groups | B Groups |
|---|---|---|
| Objective Response Rate | 268 | 115 |
DOR is defined as a period from the first documentation of response (CR or PR) through the first documentation of PD or death (whichever occurs first).
| month | A Groups | B Groups |
|---|---|---|
| Duration of Response | 6.80 (5.520 to 8.345) | 4.17 (3.055 to 4.205) |
Collected over From ICF until 90 days after the last study treatment (up to approximately 56 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group A | 224/389 (57.6%) | 146/389 (37.5%) | 367/389 (94.3%) |
| Group B | 140/196 (71.4%) | 71/196 (36.2%) | 187/196 (95.4%) |
| Event | Group A | Group B |
|---|---|---|
| Disease progressionGeneral disorders | 29/389 | 19/196 |
| Neutrophil count decreasedInvestigations | 17/389 | 18/196 |
| platelet count decreasedBlood and lymphatic system disorders | 25/389 | 15/196 |
| Neutrophil count decreasedInvestigations | 17/389 | 11/196 |
| PneumoniaInfections and infestations | 14/389 | 7/196 |
| DeathGastrointestinal disorders | 11/389 | 7/196 |
| NeutropeniaBlood and lymphatic system disorders | 11/389 | 4/196 |
| ThrombocytopeniaBlood and lymphatic system disorders | 11/389 | 4/196 |
| AnaemiaBlood and lymphatic system disorders | 6/389 | 5/196 |
| LeukopeniaBlood and lymphatic system disorders | 9/389 | 3/196 |
| Event | Group A | Group B |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 279/389 | 139/196 |
| AlopeciaSkin and subcutaneous tissue disorders | 211/389 | 111/196 |
| Neutrophil count decreasedInvestigations | 217/389 | 96/196 |
| White blood cell count decreasedInvestigations | 205/389 | 98/196 |
| NauseaGastrointestinal disorders | 140/389 | 86/196 |
| Platelet count decreasedInvestigations | 157/389 | 85/196 |
| NeutropeniaBlood and lymphatic system disorders | 115/389 | 59/196 |
| ConstipationGastrointestinal disorders | 94/389 | 58/196 |
| VomitingGastrointestinal disorders | 78/389 | 58/196 |
| Decreased appetiteMetabolism and nutrition disorders | 109/389 | 56/196 |
| Age, Continuous(years) | Group A | Group B | Total |
|---|---|---|---|
| Mean | 63 (28 to 76) | 62 (31 to 83) | 62 (28 to 83) |
| Sex: Female, Male(Participants) | Group A | Group B | Total |
|---|---|---|---|
| Female | 72 | 164 | 236 |
| Male | 317 | 32 | 349 |
| Race/Ethnicity, Customized(Participants) | Group A | Group B | Total |
|---|---|---|---|
| Asian | 262 | 139 | 401 |
| Non-Asian | 127 | 57 | 184 |
| Smoking history(Participants) | Group A | Group B | Total |
|---|---|---|---|
| Never smoker | 81 | 35 | 116 |
| Current smoker | 102 | 48 | 150 |
| Former smoker | 206 | 113 | 319 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2019 to primary completion in May 2024, 55 months.
Results were first posted in Dec 2025, 1 year 7 months after primary completion.
Of 55 industry-sponsored phase 3 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 44. This study's 55 months is above that.
Counting every sponsor, half of 68 studies reached it within 41 months; a quarter within 31 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Serplulimab